scholarly journals Efficacy of Citalopram in the prevention of recurrent depression in elderly patients: Placebo-controlled study of maintenance therapy

2002 ◽  
Vol 181 (1) ◽  
pp. 29-35 ◽  
Author(s):  
René Klysner ◽  
Jesper Bent-Hansen ◽  
Hanne L. Hansen ◽  
Marianne Lunde ◽  
Elisabeth Pleidrup ◽  
...  
Keyword(s):  
Major Depression ◽  
Elderly Patients ◽  
Rating Scale ◽  
The Elderly ◽  
Term Treatment ◽  
Fixed Dose ◽  
Controlled Study ◽  
Recurrence Time ◽  
Long Term Treatment

BackgroundThe highly recurrent nature of major depression in the young and the elderly warrants long-term antidepressant treatment.AimsTo compare the prophylactic efficacy of citalopram and placebo in elderly patients; to evaluate long-term tolerability of citalopram.MethodOut-patients, ⩾65 years, with unipolar major depression (DSM – IV: 296.2 x or 296.3 x) and Montgomery – Åsberg Depression Rating Scale score ⩾22 were treated with citalopram 20–40 mg for 8 weeks. Responders continued on their final fixed dose of citalopram for 16 weeks before randomisation to double-blind treatment with citalopram or placebo for at least 48 weeks.ResultsNineteen of the 60 patients using citalopram v. 41 of the 61 patients using placebo had recurrence. Time to recurrence was significantly different between citalopram— and placebo-patients, in favour of citalopram (log-rank test, P < 0.0001). Long-term treatment was well tolerated.ConclusionsLong-term treatment with citalopram is effective in preventing recurrence of depression in the elderly and is well tolerated.

Metabolic syndrome in patients with schizophrenia receiving long-term treatment with lurasidone, quetiapine XR, or risperidone

2016 ◽  
Vol 33 (S1) ◽  
pp. S105-S105
Author(s):  
J. Newcomer ◽  
M. Tocco ◽  
A. Pikalov ◽  
H. Zheng ◽  
J. Cucchiaro ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Antipsychotic Agents ◽  
Term Treatment ◽  
Adult Patients ◽  
Fixed Dose ◽  
Controlled Study ◽  
Double Blind ◽  
Quetiapine Xr ◽  
Long Term Treatment

IntroductionLurasidone has demonstrated low propensity for metabolic disturbance in adult patients with schizophrenia in short-term studies.ObjectivesTo evaluate metabolic syndrome occurrence during long-term lurasidone treatment in patients with schizophrenia.AimsTo compare metabolic syndrome rates with lurasidone versus other antipsychotic agents.MethodsMetabolic syndrome rates (as defined by the US National Cholesterol Education Program-Adult Treatment Panel III) were evaluated in adult patients with schizophrenia treated with lurasidone in 2 long-term, active-controlled studies (quetiapine XR or risperidone). In the quetiapine XR-controlled study, patients completing a 6-week, double-blind, placebo-controlled, fixed-dose trial of lurasidone (74 mg/d or 148 mg/d) or quetiapine XR (600 mg/d) continued on double-blind, flexibly dosed lurasidone (37–148 mg/d) or quetiapine XR (200–800 mg/d) for up to 12 months. In the risperidone-controlled study, patients received double-blind, flexibly dosed lurasidone (37–111 mg/d) or risperidone (2–6 mg/d) for up to 12 months.ResultsAmong patients without metabolic syndrome at baseline in the quetiapine XR-controlled study, 2.4% (2/84) of lurasidone-treated patients and 7.4% (2/27) of quetiapine XR-treated patients developed metabolic syndrome at month 12 (P = NS). Of patients without metabolic syndrome at baseline in the risperidone-controlled study, 10.3% (12/117) and 23.2% (16/69) of lurasidone- and risperidone-treated patients, respectively, developed metabolic syndrome at month 12 (P = 0.02).ConclusionsLong-term treatment with lurasidone was associated with lower rates of metabolic syndrome in patients with schizophrenia compared to treatment with quetiapine XR or risperidone.SupportSunovion Pharmaceuticals Inc.ClinicalTrials.gov identifiersNCT00789698, NCT00641745.Disclosure of interestThe authors have not supplied their declaration of competing interest.

scholarly journals Evaluation of Small Molecule Combinations against Respiratory Syncytial Virus In Vitro

Molecules ◽  
2021 ◽  
Vol 26 (9) ◽  
pp. 2607
Author(s):  
Yuzhen Gao ◽  
Jingjing Cao ◽  
Pan Xing ◽  
Ralf Altmeyer ◽  
Youming Zhang
Keyword(s):  
Respiratory Syncytial Virus ◽  
Confidence Interval ◽  
The Elderly ◽  
Term Treatment ◽  
Fusion Inhibitors ◽  
Long Term Treatment ◽  
Statistical Program ◽  
Syncytial Virus

Respiratory syncytial virus (RSV) is a major pathogen that causes severe lower respiratory tract infection in infants, the elderly and the immunocompromised worldwide. At present no approved specific drugs or vaccines are available to treat this pathogen. Recently, several promising candidates targeting RSV entry and multiplication steps are under investigation. However, it is possible to lead to drug resistance under the long-term treatment. Therapeutic combinations constitute an alternative to prevent resistance and reduce antiviral doses. Therefore, we tested in vitro two-drug combinations of fusion inhibitors (GS5806, Ziresovir and BMS433771) and RNA-dependent RNA polymerase complex (RdRp) inhibitors (ALS8176, RSV604, and Cyclopamine). The statistical program MacSynergy II was employed to determine synergism, additivity or antagonism between drugs. From the result, we found that combinations of ALS8176 and Ziresovir or GS5806 exhibit additive effects against RSV in vitro, with interaction volume of 50 µM2% and 31 µM2% at 95% confidence interval, respectively. On the other hand, all combinations between fusion inhibitors showed antagonistic effects against RSV in vitro, with volume of antagonism ranging from −50 µM2 % to −176 µM2 % at 95% confidence interval. Over all, our results suggest the potentially therapeutic combinations in combating RSV in vitro could be considered for further animal and clinical evaluations.

Long-Term Treatment with ‘Duovent’ in Elderly Patients Affected by Chronic Obstructive Lung Disease

Respiration ◽  
1986 ◽  
Vol 50 (2) ◽  
pp. 245-248
Author(s):  
L. Cecere ◽  
G. Funaro ◽  
G. De Cataldis ◽  
P. Carnicelli ◽  
R. Pinto
Keyword(s):  
Elderly Patients ◽  
Lung Disease ◽  
Obstructive Lung Disease ◽  
Chronic Obstructive Lung Disease ◽  
Term Treatment ◽  
Chronic Obstructive ◽  
Long Term Treatment

scholarly journals Combination of oxybutynin transdermal patch and heparinoid cream for long-term treatment of overactive bladder in elderly patients

2018 ◽  
Vol 6 (1) ◽  
pp. 1
Author(s):  
Yoshihito Murakami ◽  
Hiroshi Nagae ◽  
Naomi Maehori ◽  
Hidehisa Sekijima ◽  
Kazuya Ooi
Keyword(s):  
Overactive Bladder ◽  
Elderly Patients ◽  
Term Treatment ◽  
Transdermal Patch ◽  
Long Term Treatment

Long-term treatment with leuprorelin for spinal and bulbar muscular atrophy: natural history-controlled study

2017 ◽  
Vol 88 (12) ◽  
pp. 1026-1032 ◽  
Author(s):  
Atsushi Hashizume ◽  
Masahisa Katsuno ◽  
Keisuke Suzuki ◽  
Akihiro Hirakawa ◽  
Yasuhiro Hijikata ◽  
...  
Keyword(s):  
Natural History ◽  
Muscular Atrophy ◽  
Term Treatment ◽  
Controlled Study ◽  
Long Term Treatment

scholarly journals Effect of Mirtazapine on Thyroid Hormones in Adult Patients with Major Depression

2005 ◽  
Vol 18 (4) ◽  
pp. 737-744 ◽  
Author(s):  
F. Gambi ◽  
D. De Berardis ◽  
G. Sepede ◽  
D. Campanella ◽  
N. Galliani ◽  
...  
Keyword(s):  
Major Depression ◽  
Thyroid Hormones ◽  
Treatment Period ◽  
Rating Scale ◽  
Venous Blood ◽  
Term Treatment ◽  
Free T4 ◽  
End Of Treatment ◽  
Long Term Treatment ◽  
Hpt Axis

Hypothalamic pituitary thyroid (HPT) axis abnormalities and alterations in major depression are reported in literature. The aim of our study was to evaluate the effect of mirtazapine on thyroid hormones after 6 months of therapy in a sample of adult outpatients with Major Depression (MD). 17 adult outpatients (7 men, 10 women) with MD according to DSM-IV criteria, were included in the study. All participants had to have met criteria for a major depressive episode with a score of at least 15 on the Hamilton Depression Rating Scale (HAM-D). Fasting venous blood samples were obtained for determination of serum Thyroid Stimulating Hrmone (TSH), Free T3 (FT3) and Free T4 (FT4) concentrations both at baseline and after 6 months of therapy. HAM-D scores decreased significantly from the first day of treatment to the end of the treatment period (p<0.001) and twelve patients (70.6%) were classified as responders. A significant increase in FT3 concentrations was found between baseline and the end of treatment period (P=0.015) whereas FT4 concentrations decreased (P=0.046). No significant changes were found in TSH levels. Higher FT4 concentrations at baseline predicted higher HAM-D scorers both at baseline and at the end of the treatment period. Furthermore, higher FT3 concentrations at endpoint were found to be predictors of lower HAM-D scores. Long-term treatment with mirtazapine increases FT3 levels and decreases FT4 maybe involving the deiodination process of T4 into T3.

Sign in / Sign up

Export Citation Format

Share Document